GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rhythm Pharmaceuticals Inc (STU:1RV) » Definitions » Operating Cash Flow per Share

Rhythm Pharmaceuticals (STU:1RV) Operating Cash Flow per Share : €-1.89 (TTM As of Sep. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Rhythm Pharmaceuticals Operating Cash Flow per Share?

Rhythm Pharmaceuticals's operating cash flow per share for the three months ended in Sep. 2024 was €-0.37. Rhythm Pharmaceuticals's operating cash flow per share for the trailing twelve months (TTM) ended in Sep. 2024 was €-1.89.

During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 5.10% per year. During the past 5 years, the average Operating Cash Flow per Share Growth Rate was -2.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.

The historical rank and industry rank for Rhythm Pharmaceuticals's Operating Cash Flow per Share or its related term are showing as below:

STU:1RV' s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: -68.7   Med: -10.65   Max: 5.1
Current: 5.1

During the past 9 years, Rhythm Pharmaceuticals's highest 3-Year average Operating Cash Flow per Share Growth Rate was 5.10% per year. The lowest was -68.70% per year. And the median was -10.65% per year.

STU:1RV's 3-Year OCF Growth Rate is ranked better than
52.72% of 1197 companies
in the Biotechnology industry
Industry Median: 3.5 vs STU:1RV: 5.10

Rhythm Pharmaceuticals Operating Cash Flow per Share Historical Data

The historical data trend for Rhythm Pharmaceuticals's Operating Cash Flow per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rhythm Pharmaceuticals Operating Cash Flow per Share Chart

Rhythm Pharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Operating Cash Flow per Share
Get a 7-Day Free Trial Premium Member Only -3.03 -2.27 -2.61 -3.14 -2.17

Rhythm Pharmaceuticals Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Operating Cash Flow per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.47 -0.46 -0.62 -0.44 -0.37

Competitive Comparison of Rhythm Pharmaceuticals's Operating Cash Flow per Share

For the Biotechnology subindustry, Rhythm Pharmaceuticals's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rhythm Pharmaceuticals's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rhythm Pharmaceuticals's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Rhythm Pharmaceuticals's Price-to-Operating-Cash-Flow falls into.



Rhythm Pharmaceuticals Operating Cash Flow per Share Calculation

Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.

Rhythm Pharmaceuticals's Operating Cash Flow per Share for the fiscal year that ended in Dec. 2023 is calculated as

Operating Cash Flow per Share (A: Dec. 2023 )=Cash Flow from Operations (A: Dec. 2023 )/Shares Outstanding (Diluted Average) (A: Dec. 2023 )
=-124.856/57.673
=-2.16

Rhythm Pharmaceuticals's Operating Cash Flow per Share for the quarter that ended in Dec. 2023 is calculated as

Operating Cash Flow per Share (Q: Sep. 2024 )=Cash Flow from Operations (Q: Sep. 2024 )/Shares Outstanding (Diluted Average) (Q: Sep. 2024 )
=-22.719/61.220
=-0.37

Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-1.89

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Rhythm Pharmaceuticals Operating Cash Flow per Share Related Terms

Thank you for viewing the detailed overview of Rhythm Pharmaceuticals's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Rhythm Pharmaceuticals Business Description

Traded in Other Exchanges
Address
222 Berkeley Street, 12th Floor, Boston, MA, USA, 02116
Rhythm Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in development and commercialization of therapies for patients with rare diseases. It is focused on the development and commercialization of peptide therapeutics for the treatment of gastrointestinal, or GI, diseases, and genetic deficiencies that result in metabolic disorders. The company's product candidate is setmelanotide (RM 493), which is a potent, melanocortin 4, or MC4, receptor agonist for the treatment of rare genetic disorders of obesity caused by MC4 pathway deficiencies. Geographically the company generates its revenue from the United states, Germany, and other with the majority being generated from the United states.

Rhythm Pharmaceuticals Headlines

No Headlines